Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Verve Therapeutics Inc has a consensus price target of $18.6 based on the ratings of 14 analysts. The high is $40 issued by Stifel on April 3, 2024. The low is $11 issued by Jefferies on June 18, 2025. The 3 most-recent analyst ratings were released by BMO Capital, HC Wainwright & Co., and LifeSci Capital on June 27, 2025, June 18, 2025, and June 18, 2025, respectively. With an average price target of $13 between BMO Capital, HC Wainwright & Co., and LifeSci Capital, there's an implied 18.18% upside for Verve Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/27/2025 | 22.73% | BMO Capital | $20 → $13.5 | Downgrade | Outperform → Market Perform | |||
06/18/2025 | 22.73% | HC Wainwright & Co. | $13.5 → $13.5 | Downgrade | Buy → Neutral | |||
06/18/2025 | 9.09% | LifeSci Capital | → $12 | Downgrade | Outperform → Market Perform | |||
06/18/2025 | — | Jefferies | $28 → $11 | Downgrade | Buy → Hold | |||
06/17/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
06/17/2025 | 18.18% | Canaccord Genuity | $39 → $13 | Downgrade | Buy → Hold | |||
04/15/2025 | — | William Blair | — | Reiterates | Outperform → Outperform | |||
04/15/2025 | — | Cantor Fitzgerald | — | Upgrade | Neutral → Overweight | |||
04/15/2025 | 118.18% | Guggenheim | $18 → $24 | Maintains | Buy | |||
04/15/2025 | 254.55% | Canaccord Genuity | $32 → $39 | Maintains | Buy | |||
04/14/2025 | 127.27% | HC Wainwright & Co. | $15 → $25 | Maintains | Buy | |||
03/25/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
03/25/2025 | 36.36% | HC Wainwright & Co. | $15 → $15 | Reiterates | Buy → Buy | |||
03/04/2025 | 36.36% | RBC Capital | $17 → $15 | Maintains | Outperform | |||
02/28/2025 | 36.36% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy | |||
11/06/2024 | 190.91% | Canaccord Genuity | $29 → $32 | Maintains | Buy | |||
11/06/2024 | 54.55% | RBC Capital | $20 → $17 | Maintains | Outperform | |||
11/06/2024 | 27.27% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy | |||
08/12/2024 | 163.64% | Canaccord Genuity | $30 → $29 | Maintains | Buy | |||
08/12/2024 | 36.36% | HC Wainwright & Co. | $15 → $15 | Reiterates | Buy → Buy | |||
08/09/2024 | 81.82% | RBC Capital | $25 → $20 | Maintains | Outperform | |||
05/09/2024 | 36.36% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy | |||
04/03/2024 | 263.64% | Stifel | $56 → $40 | Maintains | Buy | |||
02/28/2024 | 218.18% | RBC Capital | $35 → $35 | Reiterates | Outperform → Outperform | |||
09/13/2023 | 100% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral | |||
08/29/2023 | 100% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral | |||
08/15/2023 | 400% | Guggenheim | $56 → $55 | Maintains | Buy | |||
08/11/2023 | 181.82% | Credit Suisse | → $31 | Reiterates | Neutral → Neutral | |||
06/16/2023 | 163.64% | Canaccord Genuity | → $29 | Reiterates | Buy → Buy | |||
05/16/2023 | 218.18% | RBC Capital | → $35 | Reiterates | Outperform → Outperform | |||
04/13/2023 | 163.64% | Canaccord Genuity | → $29 | Initiates | → Buy | |||
02/01/2023 | 90.91% | Cantor Fitzgerald | → $21 | Initiates | → Neutral | |||
12/15/2022 | 18.18% | Goldman Sachs | → $13 | Initiates | → Sell | |||
11/08/2022 | 218.18% | RBC Capital | $42 → $35 | Maintains | Outperform | |||
10/06/2022 | 336.36% | Credit Suisse | → $48 | Initiates | → Neutral | |||
08/25/2022 | 409.09% | Stifel | $32 → $56 | Upgrade | Hold → Buy | |||
07/18/2022 | 463.64% | BMO Capital | $48 → $62 | Maintains | Outperform |
The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by BMO Capital on June 27, 2025. The analyst firm set a price target for $13.50 expecting VERV to rise to within 12 months (a possible 22.73% upside). 21 analyst firms have reported ratings in the last year.
The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by BMO Capital, and Verve Therapeutics downgraded their market perform rating.
The last upgrade for Verve Therapeutics Inc happened on April 15, 2025 when Cantor Fitzgerald raised their price target to N/A. Cantor Fitzgerald previously had a neutral for Verve Therapeutics Inc.
The last downgrade for Verve Therapeutics Inc happened on June 27, 2025 when BMO Capital changed their price target from $20 to $13.5 for Verve Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a downgraded with a price target of $20.00 to $13.50. The current price Verve Therapeutics (VERV) is trading at is $11.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.